Levetiracetam Solution
Product Images NDC 39328-511

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 39328-511). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Patrin Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure diagram of the active ingredient Levetiracetam as shown in the product labeling for the oral solution 100 mg/mL by Patrin Pharma, Inc.*

FDA Label Image

Figure 1 (Levetiracetam 02)

A bar chart comparing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). Both Levetiracetam groups show statistically significant higher percentages versus placebo.*

FDA Label Image

Figure 2 (Levetiracetam 03)

A bar chart comparing the percentage of patients experiencing an outcome across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Asterisks indicate statistically significant differences versus placebo for the Levetiracetam groups.*

FDA Label Image

Figure 3 (Levetiracetam 04)

A bar chart comparing the percentage of patients between Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The chart shows approximately 14.4% for Placebo and 39.4% for Levetiracetam, with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

Figure 4 (Levetiracetam 05)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group has about 19.6% of patients, while the Levetiracetam group shows approximately 44.6%, with a statistical significance marker indicated on the Levetiracetam bar.*

FDA Label Image

Figure 5 (Levetiracetam 06)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The Placebo group shows 19.6% of patients, while the Levetiracetam group shows 43.1%, with a notation indicating the difference is statistically significant versus placebo.*

FDA Label Image

Figure 6 (Levetiracetam 07)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The chart shows 45.2% for Placebo and 72.2% for Levetiracetam, with a note indicating statistical significance versus placebo.*

FDA Label Image

Principal Display Panel (5 mL Cup Label)

The image shows a label for Levetiracetam Oral Solution USP with a strength of 500 mg/5 mL. It is an oral solution indicated for institutional use only. The label includes the NDC number 39328-511-05, a barcode, and states it is manufactured for Patrin Pharma, Inc., Skokie, IL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.